-

Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), meets the stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1) and meets all other applicable criteria for continued listing.

Aditxt recently completed a reverse stock split and closed a $20 million public offering. Amro Albanna, co-founder, chairman and CEO of Aditxt, said both events were key to the Company’s successful Nasdaq compliance and continued progress within each of the Company’s programs toward commercialization, which currently include AditxtScore™, Adimune™ and Adivir™.

About Aditxt, Inc.

Aditxt is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies.

For more information, please visit: www.Aditxt.com and www.AditxtScore.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Media and Investor Relations Contact:
ir@aditxt.com
www.aditxt.com

Industry:

Aditxt, Inc.

NASDAQ:ADTX
Release Versions
English

Contacts

Media and Investor Relations Contact:
ir@aditxt.com
www.aditxt.com

More News From Aditxt, Inc.

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be cap...

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the r...

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today shared its growth vision under the bitXbio™ strategy. bitXbio™ (pronounced “bit-by-bio”) is a transformational framework designed to connect public markets, blockchain and Web3, and digital asset treasuries for advancing breakthrough health innovations. The bitXbio™ strategy is intended to scale Aditxt as a social innovati...
Back to Newsroom